Metabolism open最新文献

{"title":"Corrigendum to “Metabolic signature across Life's Essential 8 profiles is heterogeneous and may predict cardiovascular disease and mortality” [Metabol Open 31 (2026) 100487]","authors":"Ian M. Pollack, Jiaxuan Duan, Justin Swanson, Hongtian Wang, Kevin Kip, Steven E. Reis, Chris McKennan, Anum Saeed","doi":"10.1016/j.metop.2026.100493","DOIUrl":"10.1016/j.metop.2026.100493","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"31 ","pages":"Article 100493"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148951714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Evaluation of the anti-hyperglycemic and anti-dyslipidemic potential of the hydroethanolic extract of Graptophyllum pictum (Acanthaceae) aerial parts in streptozotocin-nicotinamide-induced diabetic Wistar rats” [Metabol. Open 29 (2026) 100455]","authors":"Pradeep Singh, Garima Mishra","doi":"10.1016/j.metop.2026.100486","DOIUrl":"10.1016/j.metop.2026.100486","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"31 ","pages":"Article 100486"},"PeriodicalIF":3.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148951713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus","authors":"Prabhat Kumar Sharma ,&nbsp;V. Viswaprasad ,&nbsp;Animesh Choudhary ,&nbsp;Ansari Rizwanahmed Nurulhasan ,&nbsp;Sagar Vivek Redkar ,&nbsp;Patel Manan Bharatkumar ,&nbsp;Vijaykumar Shivajirao Patil ,&nbsp;Sumit Anand ,&nbsp;Vijaykumar Barge ,&nbsp;Shalin J. Shah ,&nbsp;Chintan B. Patel ,&nbsp;Kanugula Sudheer ,&nbsp;Shrikant Somani ,&nbsp;Konatham Rambabu ,&nbsp;Surya Veeramani Kartheek Adhikarla ,&nbsp;M. Swapna ,&nbsp;Shravan Kumar Ankathi ,&nbsp;Veer Bahadur Singh ,&nbsp;Gouranga Sarkar ,&nbsp;S.K. Gautam ,&nbsp;Hardik Pathak","doi":"10.1016/j.metop.2026.100476","DOIUrl":"10.1016/j.metop.2026.100476","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 diabetes mellitus (T2DM) is the most common non-communicable disease affecting over 89.8 million adults in India. Evidence suggests long-acting glucagon-like peptide-1 (GLP-1) receptor agonist improves glycaemic control in the patients with T2DM. This phase 3 trial compared a novel semaglutide injection developed by Zydus Lifesciences Ltd. with the reference biologic in Indian adults with T2DM inadequately controlled on metformin.</div></div><div><h3>Methods</h3><div>In this multicentre, randomised study, 314 patients aged 18–65 years with HbA1c 7.0–10.5 % were randomised 1:1 to once-weekly semaglutide injection (test) or reference semaglutide for 24 weeks. Doses were titrated according to glycaemic targets. The primary endpoint was change in HbA1c at 24 weeks (pre-specified non-inferiority margin of 0.4 percentage points). Secondary endpoints included changes in fasting and post-prandial glucose, body weight, BMI, lipid profile, blood pressure, rescue medication use, safety profile and anti-drug antibody formation. Analyses were conducted on the modified intent-to-treat (mITT) population.</div></div><div><h3>Results</h3><div>Of 314 randomised participants, 274 completed the trial (133 in the test arm and 141 in the comparator arm). HbA1c decreased from 8.36 % to 6.81 % in the test group and from 8.36 % to 6.79 % in the comparator, with a least-squares mean difference of −0.0038 % (95 % CI −0.20 to 0.19), meeting the pre-specified non-inferiority margin. Reductions in body weight (−4.59 vs −4.42 kg), BMI (−1.76 vs −1.68 kg/m²), fasting plasma glucose (−37.5 vs −39.0 mg/dL) and post-prandial plasma glucose (−54.5 vs −55.7 mg/dL) at week 24 were comparable between the groups. Treatment-emergent adverse events (TEAEs) were reported in 58.6 % of patients in the test group and 61.8 % of patients in the comparator group, respectively. Most events were mild and no serious adverse events occurred. Hypoglycaemia was infrequent and mild (1.9 % vs 0 %). Anti-drug antibodies were detected in 2.23 % of samples and had no impact on efficacy.</div></div><div><h3>Conclusions</h3><div>This novel formulation of once-weekly semaglutide injection demonstrated non-inferior glycaemic efficacy, safety &amp; immunogenicity to the reference product in Indian adults with type 2 diabetes.</div></div><div><h3>Trial registration</h3><div>Clinical Trials Registry–India (CTRI/2025/03/082615).</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"30 ","pages":"Article 100476"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensemble learning uncovers novel metabolomic biomarkers for early osteoporosis prediction in Tibetan plateau populations","authors":"Jiawei Yang ,&nbsp;Tao Zhou ,&nbsp;Haichen Zhang ,&nbsp;Qiong Zhang ,&nbsp;Lening Chen ,&nbsp;Qianqian Xiao ,&nbsp;Shusheng Luo ,&nbsp;Labasangzhu ,&nbsp;Dunyou ,&nbsp;Danbalangjie ,&nbsp;Weidong Hao ,&nbsp;Xuetao Wei","doi":"10.1016/j.metop.2026.100480","DOIUrl":"10.1016/j.metop.2026.100480","url":null,"abstract":"<div><h3>Background</h3><div>Osteoporosis represents a prevalent metabolic bone disorder among middle-aged and elderly populations, with its prevention and early detection holding important implications for clinical practice and public health. While extensive research has characterized osteoporosis in low-altitude populations, plateau regions present unique challenges.</div></div><div><h3>Methods</h3><div>This study enrolled 177 adult residents from Lhasa, Tibet. Data collection included demographic characteristics, health profiles, and female reproductive parameters. Osteoporosis is defined by T-score ≤ −2.5 (for males &gt;50 years and postmenopausal women) or Z-score ≤ −2 (for males ≤50 years and premenopausal women). Serum metabolomic profiling identified 3381 metabolites via HPLC-MS/MS. Predictive models were constructed using Least Absolute Shrinkage and Selection Operator (LASSO) and Random Forest (RF) ensemble learning algorithm, with pathway enrichment analysis performed in MetaboAnalyst (<em>P</em> &lt; 0.05).</div></div><div><h3>Results</h3><div>Our cross-sectional analysis of 177 participants revealed 41 osteoporosis cases (23.2%), predominantly postmenopausal women (36/41). Baseline characteristics showed significant differences in age, gender, difficulty initiating sleep, and menopausal status across groups (all <em>P</em> &lt; 0.05). The 9 metabolites screened by LASSO classification demonstrated exceptional predictive capacity for osteoporosis (AUC: 0.995), while 10 metabolites based on RF better predicted osteopenia progression (R²: 0.848). Z-score-based models outperformed T-score subgroups. Menopausal status and difficulty initiating sleep were identified as high-risk factors, and three metabolites—Dihydro-3-hydroxy-4,4-dimethyl-2(3H)-furanone, gamma-Glutamyltryptophan, and di-homo-gamma-linolenate—emerged as potential early indicators of bone loss. Pathway enrichment highlighted pyrimidine metabolism and related diseases as a potential therapeutic target for bone loss.</div></div><div><h3>Conclusions</h3><div>This research proposes a metabolomics-driven model for osteoporosis prediction, establishing an innovative biomarker framework for early clinical intervention in plateau areas.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"30 ","pages":"Article 100480"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in Indian adults with obesity: A phase III randomized non-inferiority trial” [Metabol Open 30 (2026) 100460]","authors":"Prabhat Kumar Sharma ,&nbsp;Sagar Vivek Redkar ,&nbsp;Abhishek Madhav Karmalkar ,&nbsp;Sumit Anand ,&nbsp;Vijaykumar Shivajirao Patil ,&nbsp;Ansari Rizwanahmed Nurulhasan ,&nbsp;Patel Manan Bharatkumar ,&nbsp;Vijaykumar Barge ,&nbsp;Shalin J. Shah ,&nbsp;Chintan B. Patel ,&nbsp;Animesh Choudhary ,&nbsp;Kanugula Sudheer ,&nbsp;Konatham Rambabu ,&nbsp;S. Narasinga Rao ,&nbsp;M. Swapna ,&nbsp;Shravan Kumar Ankathi ,&nbsp;Veer Bahadur Singh ,&nbsp;Gouranga Sarkar ,&nbsp;S.K. Gautam ,&nbsp;Kalyan Kumar Das ,&nbsp;Hardik Pathak","doi":"10.1016/j.metop.2026.100477","DOIUrl":"10.1016/j.metop.2026.100477","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"30 ","pages":"Article 100477"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148241470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What's in a name? From PCOS to polyendocrine metabolic ovarian syndrome: A metabolic reframing, promise, controversies, and challenges ahead","authors":"Maria Dalamaga","doi":"10.1016/j.metop.2026.100479","DOIUrl":"10.1016/j.metop.2026.100479","url":null,"abstract":"<div><div>In medicine, nomenclature shapes diagnostic reasoning, clinical pathways, research priorities, and patients' understanding of their condition. Polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of reproductive age, affecting one in eight women and more than 170 million individuals worldwide, has long carried a name that foregrounds ovarian morphology and implies pathological cysts. This framing has narrowed clinical attention, contributed to delayed diagnosis in up to 70% of affected individuals, and obscured the broader endocrine, metabolic, psychological, and cardiometabolic dimensions of the syndrome. A recent global consensus process led by the Global Name Change Consortium, involving 56 organizations, patients, clinicians, and researchers, has renamed the condition polyendocrine metabolic ovarian syndrome (PMOS). The new terminology recognizes interacting disturbances in androgen production, insulin signaling, neuroendocrine regulation, and ovarian function, while centering metabolic features such as insulin resistance, dysglycemia, dyslipidemia, cardiovascular risk, and metabolic dysfunction-associated steatotic liver disease. This editorial examines the historical evolution of diagnostic criteria from the 1990 NIH criteria through the 2003 Rotterdam consensus to the 2023 International Evidence-Based Guideline, reviews the structured renaming process, and draws parallels with the transition from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD). It discusses controversies surrounding the new name, implementation challenges, and the infrastructure needed to ensure that PMOS improves diagnostic accuracy, broadens multidisciplinary care, and reduces stigma without compromising the existing evidence base.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"30 ","pages":"Article 100479"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148241475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early ICU glycemic trajectory phenotypes predict short- and long-term mortality in critically ill patients: a dual-database cohort study","authors":"Deyu Kong ,&nbsp;Yang Long ,&nbsp;Tingting Huang ,&nbsp;Yonghu Zhang ,&nbsp;Wen-Jie Liu ,&nbsp;Cheng-Xi Liu ,&nbsp;Shan Liu","doi":"10.1016/j.metop.2026.100478","DOIUrl":"10.1016/j.metop.2026.100478","url":null,"abstract":"<div><h3>Aims</h3><div>Dysglycemia is common in critically ill patients and is associated with adverse outcomes, but the prognostic significance of early ICU glycemic patterns remains unclear.</div></div><div><h3>Methods</h3><div>In this dual-database cohort study, 60,365 critically ill patients from MIMIC-IV were used for model development and 81,237 from eICU for external validation. Early blood glucose trajectories were clustered using dynamic time warping (DTW). Associations with mortality were assessed using survival and multivariable regression analyses. Least Absolute Shrinkage and Selection Operator (LASSO)-selected predictors were incorporated into machine-learning models, which were externally validated and interpreted using SHapley Additive exPlanations (SHAP).</div></div><div><h3>Results</h3><div>Four glycemic trajectory phenotypes were identified in both cohorts. A rising stress hyperglycemia-like trajectory was consistently associated with the highest mortality risk. In MIMIC-IV, this phenotype was associated with higher in-hospital, 180-day, and 1-year mortality; in eICU, it was also associated with the highest in-hospital mortality. Machine-learning models integrating trajectory phenotype with other clinical variables outperformed Simplified Acute Physiology Score II (SAPS II) and Oxford Acute Severity of Illness Score (OASIS). Random Forest was selected as the representative model, and a web-based tool was developed for individualized risk estimation.</div></div><div><h3>Conclusions</h3><div>A rising stress hyperglycemia-like phenotype identifies a high-risk subgroup of critically ill patients and may improve mortality risk stratification beyond conventional severity scores.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"30 ","pages":"Article 100478"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional status and clinical outcomes in the intensive care unit: A global systematic review and meta-analysis","authors":"Misrak Weldeyohanes,&nbsp;Zelalem Debebe,&nbsp;Zeweter Abebe","doi":"10.1016/j.metop.2026.100450","DOIUrl":"10.1016/j.metop.2026.100450","url":null,"abstract":"<div><h3>Background</h3><div>The severity of illness and inability to eat while in the intensive care unit put ICU patients at high risk of malnutrition. Nutritional status assessment is vital for managing patients’ morbidity, length of stay, and mortality. This systematic review aimed to assess the nutritional status of adult ICU patients and evaluate the influence of malnutrition on clinical outcomes.</div></div><div><h3>Methods</h3><div>A comprehensive systematic review of articles published 2010 to 2024 was conducted Google Scholar, PubMed, Scopus, Web of Science, Cochrane, and Embase included, studies focusing on nutritional status in adult ICU patients. A random-effects meta-analysis model was performed via STATA 17 to determine the overall prevalence of malnutrition among the ICU patients and a forest plot was generated to visually depict the pooled estimate and individual study results. Publication bias was assessed using Egger's test and funnel plots. Heterogeneity was evaluated using I2 and Baujat plots.</div></div><div><h3>Results</h3><div>This systematic review included prospective and retrospective cohort and cross-sectional studies, 31 publications with a sample size of 21,413 patients. The pooled prevalence of malnutrition was 32.74 (95% confidence interval: 19.9--45.5,I² = 0.0%, τ² = 0.00) and the average length of stay for malnourished patients was 5.6 (2.920, 8.265) days. Malnourished patients had an overall risk of mortality of 1.45 (95% CI: 0.76–2.13).</div></div><div><h3>Conclusion</h3><div>Malnutrition is prevalent among adult ICU patients, with wide variation across studies, and the situation becomes worse after admission. Additionally, malnourished patients have longer hospital stays and are more likely to die than well-nourished patients.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"29 ","pages":"Article 100450"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147396580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a virtual Culinary medicine curriculum on fatty acid profiles in medical students","authors":"Selina Böttcher ,&nbsp;Thomas Ellrott ,&nbsp;Miriam Rabehl ,&nbsp;Can G. Leineweber ,&nbsp;Chaoxuan Wang ,&nbsp;Uwe Neumann ,&nbsp;Anne Pietzner ,&nbsp;Christoph Schmöcker ,&nbsp;Karsten H. Weylandt","doi":"10.1016/j.metop.2025.100431","DOIUrl":"10.1016/j.metop.2025.100431","url":null,"abstract":"<div><h3>Background</h3><div>Culinary Medicine (CM) has gained increasing popularity as an educational approach to improve nutrition-related competencies among healthcare professionals. Previous studies have demonstrated increased counseling competencies, but also improvements in dietary behaviors among participants, however, objective biomarker-based evidence of such behavioral changes remains scarce. This pilot study aimed to explore preliminary effects of a CM course on biochemical and anthropometric parameters, and to evaluate the feasibility of biomarker assessment among medical students.</div></div><div><h3>Methods</h3><div>In this exploratory pre-post study, medical students completed a 20-h virtual CM curriculum. Blood samples were collected before and after the course to assess lipid parameters, HbA1c, erythrocyte fatty acid compositions, and body weight.</div></div><div><h3>Results</h3><div>Of 30 enrolled students, 13 participated in the biomarker assessment. There were slight non-significant decreases in Body Mass Index (−0.08 kg/m², <em>p</em> = 0.07) and standard laboratory lipid parameters, including LDL Cholesterol (−0.08 mmol/L, <em>p</em> = 0.598) and total cholesterol (−0.12 mmol/L, <em>p</em> = 0.493). Significant alterations in erythrocyte fatty acids were detected with a slight increase in saturated fatty acids (+0.78 %, <em>p</em> = 0.004) and, in particular, monounsaturated fatty acids (+1.04 %, <em>p</em> = 0.004), accompanied by a significant decrease in n-6 polyunsaturated fatty acids (−2.28 %, <em>p</em> = 0.003).</div></div><div><h3>Discussion</h3><div>This pilot study demonstrates the feasibility of conducting biomarker-based evaluations within a CM curriculum and provides preliminary biochemical evidence supporting previous self-reported findings of dietary behavior change. The study illustrates a promising approach for integrating objective outcome measures into CM education and informs the design of future, adequately powered trials.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"29 ","pages":"Article 100431"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adipogenin-seipin, lipid droplet architecture and the expanding metabolic frontier: Implications for metabolic disorders and cancer","authors":"Maria Dalamaga","doi":"10.1016/j.metop.2025.100439","DOIUrl":"10.1016/j.metop.2025.100439","url":null,"abstract":"<div><div>Recent work by Li et al. identifying adipogenin as a structural cofactor of seipin introduces a new paradigm in lipid droplet (LD) biology, shifting attention from enzymatic control of lipid synthesis toward organelle architecture as a determinant of metabolic disease. By stabilizing a dodecameric seipin complex, adipogenin redirects triacylglycerol flux from LD nucleation to droplet expansion, thereby promoting LD enlargement, adipocyte hypertrophy and adipose tissue growth. This mechanism refines the adipose tissue expandability hypothesis by highlighting the importance of endoplasmic reticulum–LD interfaces and their associated microproteins in determining lipid storage capacity. Beyond adipose tissue, LDs have emerged as multifunctional organelles in cancer, supporting metabolic flexibility, redox homeostasis, hypoxia adaptation and resistance to cytotoxic therapies. Although adipogenin expression appears restricted to adipocytes, the structural principle it exemplifies, i.e. that small ER-embedded cofactors may modulate seipin assemblies and LD dynamics, may extend to malignant cells through yet-unidentified microproteins. Collectively, these observations position LD architecture as a conceptual model linking obesity, associated metabolic disorders, as well as cancer pathogenesis, suggesting that targeting organelle-level regulation, rather than lipid metabolism alone, may open new avenues for potential therapeutic interventions.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"29 ","pages":"Article 100439"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147649452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}